Search results
Showing 61 to 74 of 74 results for metastatic prostate cancer
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.
Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)
This evidence summary has been updated and replaced by NICE guideline NG131.
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Discontinued Reference number: GID-TA11252
This guidance has been updated and replaced by NICE technology appraisal guidance 887.
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
This guidance has been updated and replaced by NICE technology appraisal guidance 391.
This guidance has been updated and replaced by NICE guideline CG175.
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
Our landmark review demonstrates a new approach to keeping NHS care up-to-date and could benefit thousands of adults with metastatic prostate cancer.
People living with metastatic prostate cancer in England will gain access to a new treatment combination from today (Friday, 24 October), following a recommendation by NICE.
NICE recommends olaparib for early breast cancer and metastatic prostate cancer
Deals for anti-cancer medicine olaparib have paved the way for hundreds to benefit as NICE recommends it for some types of early breast cancer and advanced prostate cancer.